HALEOSLABS

HALEOS LABS LIMITED

Active Pharmaceutical Ingredients and intermediates manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

haleoslabs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-19

Stock price
₹1538.30
Market cap
465 Cr
Stock P/E
29.4
P/B
2.18
Dividend yield
0.1%
ROE (FY26)
7.5%
ROCE (FY26)
9.4%
Operating margin (FY26)
8.8%
Debt / equity (FY26)
0.51
OCF / EBITDA (FY26)
83.3%
OCF / EBITDA (3Y)
79.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Haleos Labs (formerly SMS Lifesciences India) makes the active ingredients (APIs) and intermediate chemicals that generic and innovator drug companies use to produce medicines, selling about 40% of its output abroad and the rest in India.

Company snapshot

99thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales69 Cr72 Cr90 Cr93 Cr78 Cr85 Cr89 Cr83 Cr81 Cr95 Cr75 Cr73 Cr
Operating expenses (approx.)61 Cr63 Cr79 Cr76 Cr70 Cr72 Cr82 Cr71 Cr68 Cr81 Cr71 Cr64 Cr
EBITDA8 Cr9 Cr11 Cr16 Cr9 Cr13 Cr7 Cr12 Cr14 Cr14 Cr4 Cr9 Cr
OPM %11.4%12.9%12.6%17.6%10.9%15.1%8.3%14.2%16.7%14.8%5.5%12.5%
Other income0.34 Cr0.58 Cr2 Cr0.44 Cr2 Cr0.06 Cr2 Cr1.00 Cr0.42 Cr0.18 Cr2 Cr0.46 Cr
Interest3 Cr2 Cr3 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr1 Cr2 Cr
Depreciation4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr
Profit before tax2 Cr4 Cr7 Cr11 Cr5 Cr7 Cr4 Cr7 Cr8 Cr9 Cr0.91 Cr3 Cr
Tax %126.7%-8.2%8.8%33.3%29.8%29.8%11.3%37.6%24.3%24.3%62.0%46.5%
Net profit-0.44 Cr4 Cr6 Cr7 Cr3 Cr5 Cr3 Cr4 Cr6 Cr7 Cr0.34 Cr2 Cr
EPS (₹)₹2.20₹14.24₹19.53₹23.15₹15.46₹18.08₹9.83₹13.75₹20.19₹21.89₹1.44₹8.75

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales378 Cr261 Cr266 Cr350 Cr316 Cr306 Cr345 Cr334 CrSign in free for the trailing twelve months
Operating expenses (approx.)343 Cr235 Cr235 Cr316 Cr287 Cr275 Cr300 Cr289 CrSign in free for the trailing twelve months
EBITDA35 Cr25 Cr30 Cr34 Cr29 Cr31 Cr45 Cr45 CrSign in free for the trailing twelve months
OPM %9.2%9.7%11.4%9.8%9.1%10.2%13.1%13.4%Sign in free for the trailing twelve months
Other income3 Cr2 Cr2 Cr2 Cr3 Cr4 Cr5 Cr2 CrSign in free for the trailing twelve months
Interest6 Cr5 Cr5 Cr6 Cr7 Cr10 Cr9 Cr6 CrSign in free for the trailing twelve months
Depreciation6 Cr8 Cr8 Cr10 Cr11 Cr15 Cr15 Cr15 CrSign in free for the trailing twelve months
Profit before tax25 Cr15 Cr20 Cr33 Cr17 Cr10 Cr26 Cr25 CrSign in free for the trailing twelve months
Tax %29.7%30.6%30.7%22.7%31.4%35.7%28.5%29.4%Sign in free for the trailing twelve months
Net profit18 Cr10 Cr14 Cr25 Cr11 Cr6 Cr19 Cr18 CrSign in free for the trailing twelve months
EPS (₹)₹59.03₹33.68₹44.84₹83.68₹37.92₹30.08₹66.51₹57.26Sign in free for the trailing twelve months
Dividend payout %——0.0%1.8%4.0%7.2%2.4%2.5%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr
Reserves103 Cr113 Cr126 Cr149 Cr166 Cr174 Cr194 Cr211 Cr
Borrowings40 Cr58 Cr64 Cr77 Cr99 Cr98 Cr84 Cr109 Cr
Other liabilities123 Cr79 Cr109 Cr115 Cr108 Cr99 Cr94 Cr116 Cr
Total liabilities270 Cr253 Cr302 Cr357 Cr395 Cr391 Cr390 Cr454 Cr
Fixed assets (net)100 Cr106 Cr112 Cr140 Cr227 Cr221 Cr230 Cr267 Cr
CWIP3 Cr16 Cr38 Cr51 Cr0.85 Cr6 Cr0.40 Cr10 Cr
Investments0.04 Cr0.04 Cr0.04 Cr0.04 Cr0.04 Cr0.04 Cr0.04 Cr0.04 Cr
Inventories81 Cr64 Cr62 Cr85 Cr86 Cr81 Cr67 Cr80 Cr
Trade receivables41 Cr22 Cr34 Cr34 Cr46 Cr51 Cr69 Cr61 Cr
Cash & bank2 Cr2 Cr9 Cr0.99 Cr1 Cr0.57 Cr0.50 Cr1 Cr
Other assets41 Cr43 Cr47 Cr46 Cr34 Cr30 Cr23 Cr35 Cr
Total assets270 Cr253 Cr302 Cr357 Cr395 Cr391 Cr390 Cr454 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity30 Cr15 Cr35 Cr-11 Cr15 Cr24 Cr34 Cr37 Cr
Cash from investing-44 Cr-27 Cr-26 Cr-7 Cr-31 Cr-18 Cr-15 Cr-58 Cr
Cash from financing15 Cr12 Cr-3 Cr11 Cr17 Cr-7 Cr-19 Cr21 Cr
Net cash flow1 Cr-0.03 Cr6 Cr-8 Cr0.29 Cr-0.71 Cr-0.07 Cr0.71 Cr
Free cash flow (OCF − Capex)6 Cr-9 Cr-0.39 Cr-62 Cr-34 Cr3 Cr19 Cr-21 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %21.1%11.4%12.5%16.1%8.2%6.9%11.8%9.4%
ROE %16.8%8.8%10.5%15.3%6.1%4.7%9.5%7.5%
Debtor days4030473553617367
Inventory days110160166151183197164198
Days payable133122165139127144129152
Cash conversion cycle17684848110115107113
OCF / EBITDA %86.3%57.3%116.5%-32.9%51.1%78.1%75.6%83.3%
OCF / EBITDA % (3 years)——88.3%42.9%41.5%29.5%69.6%79.1%
Debt / equity0.380.500.500.510.590.550.430.51
Current ratio1.141.231.111.151.191.071.061.04
Net debt / EBITDA1.09———3.393.121.852.41